ARA-290
ARA-290 is a recovery peptide used in evidence-based, physician-supervised protocols. Use for chronic pain, small fiber neuropathy, CRPS, inflammatory conditions unresponsive to standard therapy.
What is ARA-290?
Non-hematopoietic erythropoietin analogue. Binds innate repair receptor (IRR/beta-common receptor) without EPO's hematopoietic effects. Potent anti-inflammatory via NF-kB/TNF-alpha suppression, neuroprotective, promotes tissue healing. RECONSTITUTION CRITICAL: Use pH 7.4 PBS only — bacteriostatic water denatures this peptide.
Uses & clinical decision logic
Use for chronic pain, small fiber neuropathy, CRPS, inflammatory conditions unresponsive to standard therapy. Higher dose range studied in clinical trials for neuropathic pain.
ARA-290 dosage & administration
| Vial size | BAC water | Dosing range | Units / dose | Frequency | Route |
|---|---|---|---|---|---|
| 10mg | 2mL PBS | 1.6-4mg | 32-80 units | 5-7 days/week x 30 days | SubQ |
Safety & contraindications
Do not use bacteriostatic water (will degrade peptide). Monitor CBC if used long-term.
Stacking & combinations
Compatible with BPC-157 for combined anti-inflammatory/angiogenic effect; pairs with SS-31 for mitochondrial neuroprotection.
Related peptides
Frequently asked questions
What is ARA-290 used for?
Use for chronic pain, small fiber neuropathy, CRPS, inflammatory conditions unresponsive to standard therapy. Higher dose range studied in clinical trials for neuropathic pain.
What is the typical ARA-290 dosage?
Common dosing ranges from 1.6-4mg (5-7 days/week x 30 days, SubQ). Exact dosing is individualized and set by a licensed physician.
How is ARA-290 administered?
ARA-290 is typically administered via SubQ.
What are the contraindications for ARA-290?
Do not use bacteriostatic water (will degrade peptide). Monitor CBC if used long-term.
Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.
Build your protocol →This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.